[1] Hruska, K.A. and Mathew, S. (2011) The Roles of the Skeleton and Phosphorus in the CKD Mineral Bone Disorder. Advances in Chronic Kidney Disease, 18, 98-104.
https://doi.org/10.1053/j.ackd.2011.01.001
[2] Taniguchi, M., Fukagawa, M., Fujii, N., Hamano, T., Shoji, T., Yokoyama, K., et al. (2013) Serum Phosphate and Calcium Should Be Primarily and Consistently Controlled in Prevalent Hemodialysis Patients. Therapeutic Apheresis and Dialysis, 17, 221-228.
https://doi.org/10.1111/1744-9987.12030
[3] Chiu, Y.W., Teitelbaum, I., Misra, M., de Leon, E.M., Adzize, T. and Mehrotra, R. (2009) Pill Burden, Adherence, Hyperphosphatemia, and Quality of Life in Maintenance Dialysis Patients. Clinical Journal of American Society of Nephrology, 4, 1089-1096.
https://doi.org/10.2215/CJN.00290109
[4] Isakova, T., Gutierrez, O.M., Chang, Y., Shah, A., Tamez, H., Smith, K., et al. (2009) Phosphorus Binders and Survival on Hemodialysis. Journal of American Society of Nephrology, 20, 388-396.
https://doi.org/10.1681/ASN.2008060609
[5] Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney International Supplement, 113, S1-S130.
[6] Price, P.A., Thomas, G.R., Pardini, A.W., Fiqueira, W.F., Capulo, J.M. and Williamson, M.K. (2002) Discovery of a High Molecular Weight Complex of Calcium, Phosphate, Fetuin, and Matrix Gamma-Carboxyglutamic Acid Protein in the Serum of Etidronate-Treated Rats. Journal of Biological Chemistry, 277, 3926-3934.
https://doi.org/10.1074/jbc.M106366200
[7] Hamano, T., Matsui, I., Mikami, S., Tomida, K., Fujii, N., Imai, E., et al. (2010) Fetuin-Mineral Complex Reflects Extraosseous Calcification Stress in CKD. Journal of American Society of Nephrology, 21, 1998-2007.
https://doi.org/10.1681/ASN.2009090944
[8] Smith, E.R., Ford, M.L., Tomlinson, L.A., Rajkumar, C., McMahon, L.P. and Holt, S.G. (2012) Phosphorylated Fetuin A-Containing Calciprotein Particles Are Associated with Aortic Stiffness and a Procalcific Milieu in Patients with Pre-Dialysis CKD. Nephrology Dialysis Transplantation, 27, 1957-1966.
https://doi.org/10.1093/ndt/gfr609
[9] Miura, Y., Iwazu, Y., Shiizaki, K., Akimoto, T., Kotani, K., Kurabayashi, M., et al. (2018) Identification of Plasma Calciprotein Particles with Distinct Physical Properties in Patients with Chronic Kidney Disease. Scientific Reports, 8, Article No. 1256.
https://doi.org/10.1038/s41598-018-19677-4
[10] Yang, W.C., Yang, C.S., Hou, C.C., Wu, T.H., Young, E.W. and Hsu, C.H. (2002) An Open-Label, Crossover Study of a New Phosphate-Binding Agent in Haemodialysis Patients: Ferric Citrate. Nephrology Dialysis Transplantation, 17, 265-270.
https://doi.org/10.1093/ndt/17.2.265
[11] Yokoyama, K., Hirakata, H., Akiba, T., Sawada, K. and Kumagai, Y. (2012) Effect of Oral JTT-751 (Ferric Citrate) on Hyperphosphatemia in Hemodialysis Patients: Results of a Randomized, Double-Blind, Placebo-Control Trial. American Journal of Nephrology, 36, 478-487.
https://doi.org/10.1159/000344008
[12] Umanath, K., Sika, M., Niecestro, R., Connelly, C., Schulman, G., Koury, M.J., et al. (2013) Rationale and Study Design of a Three-Period, 58-Week Trial of Ferric Citrate as a Phosphate Binder in Patients with ESRD on Dialysis. Hemodialysis International, 17, 67-74.
https://doi.org/10.1111/j.1542-4758.2012.00711.x
[13] Ogawa, T., Ishida, H., Matsuda, N., Fujiu, A., Matsuda, A., Ito, K., et al. (2009) Simple Evaluation of Aortic Arch Calcification by Chest Radiography in Hemodialysis Patients. Hemodialysis International, 13, 301-306.
https://doi.org/10.1111/j.1542-4758.2009.00366.x
[14] Akiyama, K., Mochizuki, T., Kataoka, H., Tsuchiya, K. and Nitta, K. (2017) Fibroblast Growth Factor 23 and Soluble Klotho in Patients with Autosomal Dominant Polycystic Kidney Disease. Nephrology (Carlton), 22, 848-853.
https://doi.org/10.1111/nep.12862
[15] Daugirdas, J.T. (1993) Second Generation Logarithmic Estimates of Single-Pool Variable Volume Kt/V: An Analysis of Error. Journal of American Society of Nephrology, 4, 1205-1213.
[16] Shinzato, T., Nakai, S., Fujita, Y., Takai, I., Morita, H., Nakane, K., et al. (1994) Determination of Kt/V and Protein Catabolic Rate Using Pre- and Postdialysis Blood Urea Nitrogen Concentrations. Nephron, 67, 280-290.
https://doi.org/10.1159/000187980
[17] Akiyama, K., Kimura, T. and Shiizaki, K. (2018) Biological and Clinical Effects of Calciprotein Particles on Chronic Kidney Disease-Mineral and Bone Disorder. International Journal of Endocrinology, 2018, Article ID: 5282389.
https://doi.org/10.1155/2018/5282389
[18] Sinsakul, M., Sika, M., Koury, M., Shapiro, W., Greene, T., Dwyer, J., et al. (2012) The Safety and Tolerability of Ferric Citrate as a Phosphate Binder in Dialysis Patients. Nephron Clinical Practice, 121, c25-c29.
https://doi.org/10.1159/000341922
[19] Dwyer, J.P., Sika, M., Schulman, G., Chang, I.J., Anger, M., Smith, M., et al. (2013) Dose-Response and Efficacy of Ferric Citrate to Treat Hyperphosphatemia in Hemodialysis Patients: A Short-Term Randomized Trial. American Journal of Kidney Disease, 61, 759-766.
https://doi.org/10.1053/j.ajkd.2012.11.041
[20] Iida, A., Kemmochi, Y., Kakimoto, K., Tanimoto, M., Mimura, T., Shinozaki, Y., et al. (2013) Ferric Citrate, a New Phosphate Binder, Prevents the Complications of Secondary Hyperparathyroidism and Vascular Calcification. American Journal of Nephrology, 37, 346-358.
https://doi.org/10.1159/000348805
[21] Pasch, A., Fareses, S., Graber, S., Wald, J., Richtering, W., Floege, J., et al. (2012) Nanoparticle-Based Test Measures Overall Propensity for Calcification in Serum. Journal of American Society of Nephrology, 23, 1744-1752.
https://doi.org/10.1681/ASN.2012030240
[22] Aghagolzadeh, P., Bachtler, M., Bijamia, R., Jackson, C., Smith, E.R., Odermatt, A., et al. (2016) Calcification of Vascular Smooth Muscle Cells Is Induced by Secondary Calciprotein Particles and Enhanced by Tumor Necrosis Factor-α. Atherosclerosis, 251, 404-414.
https://doi.org/10.1016/j.atherosclerosis.2016.05.044
[23] Matsui, I., Hamano, T., Mikami, S., Fujii, N., Takabatake, Y., Nagasawa, Y., et al. (2009) Fully Phosphorylated Fetuin-A Forms a Mineral Complex in the Serum of Rats with Adenine-Induced Renal Failure. Kidney International, 75, 915-928.
https://doi.org/10.1038/ki.2008.700
[24] Herrmann, M., Schafer, C., Heiss, A., Graber, S., Kinkeldey, A., Buscher, A., et al. (2012) Clearance of Fetuin-A-Containing Calciprotein Particles Is Mediated by Scavenger Receptor-A. Circulation Research, 111, 575-584.
https://doi.org/10.1161/CIRCRESAHA.111.261479
[25] Nitta, K., Hanafusa, N., Okazaki, M., Komatsu, M., Kawaguchi, H. and Tsuchiya, K. (2018) Association between Risk Factors Including Bone-Derived Biomarkers and Aortic Arch Calcification in Maintenance Hemodialysis Patients. Kidney Blood Pressure Research, 43, 1554-1562.
https://doi.org/10.1159/000494441
[26] Ogawa, T. and Nitta, K. (2018) Pathogenesis and Management of Vascular Calcification in Patients with End-Stage Renal Disease. Contribution to Nephrology, 196, 71-77.
https://doi.org/10.1159/000485702
[27] Qunibi, W.Y. (2007) Cardiovascular Calcification in Nondialyzed Patients with Chronic Kidney Disease. Seminar in Dialysis, 20, 134-138.
https://doi.org/10.1111/j.1525-139X.2007.00260.x
[28] Lewis, J.B., Sika, M., Koury, M.J., Chuang, P., Schulman, G., Smith, M.T., et al. (2015) Ferric Citrate Controls Phosphorus and Delivers Iron in Patients on Dialysis. Journal of the American Society of Nephrology, 26, 493-503.
https://doi.org/10.1681/ASN.2014020212
[29] Umanath, K., Jalal, D.I., Greco, B.A., Umeukeje, E.M., Reisin, E., Manley, J., et al. (2015) Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD. Journal of American Society of Nephrology, 26, 2578-2587.
https://doi.org/10.1681/ASN.2014080842
[30] Yokoyama, K., Akiba, T., Fukagawa, M., Nakayama, M., Sawada, K., Kumagai, Y., et al. (2014) A Randomized Trial of JTT-751 versus Sevelamer Hydrochloride in Patients on Hemodialysis. Nephrology Dialysis Transplantation, 29, 478-487.
https://doi.org/10.1093/ndt/gft483
[31] Lee, C.T., Wu, I.W., Chiang, S.S., Peng, Y.S., Shu, K.H., Wu, M.J., et al. (2015) Effect of Oral Ferric Citrate on Serum Phosphorus in Hemodialysis Patients: Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. Journal of Nephrology, 28, 105-113.
https://doi.org/10.1007/s40620-014-0108-6
[32] Ketteler, M., Liangos, O. and Biggar, P.H. (2016) Treating Hyperphosphatemia-Current and Advancing Drugs. Expert Opinion on Pharmacotherapy, 17, 1873-1879.
https://doi.org/10.1080/14656566.2016.1220538